Research programme: soluble Fc receptors - Sanofi Genzyme/MacroGenicsAlternative Names: GMR 321
Latest Information Update: 15 Dec 2016
At a glance
- Originator Genzyme Corporation; MacroGenics
- Class Proteins
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 29 Mar 2006 Preclinical trials in Immunological disorders in USA (unspecified route)